MPG.eBooks - Description: Clinical review report: Vortioxetine hydrobromide (Trintellix) (Lundbeck Canada Inc.)

Cover Image

Read Now

Clinical review report: Vortioxetine hydrobromide (Trintellix) (Lundbeck Canada Inc.) indication: the treatment of major depressive disorder in adults

The objective of this report was to perform a systematic review of the beneficial and harmful effects of vortioxetine 5 mg, 10 mg, and 20 mg oral tablets for the treatment of Major depressive disorder in adults

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH 2020, November 2020
Edition:	Corrected version with redactions
Series:	CADTH common drug review
Subjects:	Vortioxetine / Therapeutic Use Adult Canada Depressive Disorder, Major / Drug Therapy Antidepressive Agents / Therapeutic Use Treatment Outcome
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK564560
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this report was to perform a systematic review of the beneficial and harmful effects of vortioxetine 5 mg, 10 mg, and 20 mg oral tablets for the treatment of Major depressive disorder in adults
Physical Description:	1 PDF file (181 pages) illustrations